Maternal transfer of RSV immunity in cotton rats vaccinated during pregnancy

Vaccine
Jorge C G BlancoMarina S Boukhvalova

Abstract

Respiratory Syncytial Virus (RSV) is the leading cause of pneumonia and bronchiolitis in infants, resulting in significant morbidity and mortality worldwide. There is currently no RSV vaccine. Although maternal serum antibodies against RSV are efficiently transferred through placenta protecting human infants from RSV-induced disease, this protection is short-lived and the methods for extending and augmenting protection are not known. The objective of this study was to develop an animal model of maternal RSV vaccination using the Sigmodon hispidus cotton rat. Naïve or RSV-primed female cotton rats were inoculated with live RSV and set in breeding pairs. Antibody transfer to the litters was quantified and the offspring were challenged with RSV at different ages for analysis of protection against viral replication and lung inflammation. There was a strong correlation between RSV-neutralizing antibody (NA) titers in cotton rat mothers and their pups, which also correlated with protection of litters against virus challenge. Passive protection was short-lived and strongly reduced in animals at 4 weeks after birth. Protection of litters was significantly enhanced by inoculating mothers parenterally with live RSV and inversely correlat...Continue Reading

References

Nov 1, 1996·American Journal of Reproductive Immunology : AJRI·A MalekH Schneider
Feb 7, 2009·The New England Journal of Medicine·Caroline Breese HallPeter Szilagyi
Mar 20, 2013·Current Opinion in Infectious Diseases·Benjamin LindseyChristine Jones
Mar 4, 2014·The Journal of Pediatrics·James D NordinUNKNOWN Vaccine Safety Datalink
Jun 7, 2014·The Journal of Infectious Diseases·Helen Y ChuJanet A Englund
Dec 9, 2014·Human Vaccines & Immunotherapeutics·Michelle H Moniz, Richard H Beigi

❮ Previous
Next ❯

Citations

Mar 10, 2017·International Journal of Molecular Sciences·Emma Rey-Jurado, Alexis M Kalergis
May 18, 2018·Human Vaccines & Immunotherapeutics·Jorge C G BlancoStefanie N Vogel
May 18, 2018·Antiviral Chemistry & Chemotherapy·M S BoukhvalovaJcg Blanco
Jul 7, 2019·Vaccines·Sarah WilmschenJanine Kimpel
May 17, 2018·Nature Communications·Jorge C G BlancoTrudy G Morrison
May 28, 2019·Frontiers in Microbiology·María José Altamirano-LagosAlexis M Kalergis
Jul 31, 2021·Virus Research·Shaheer Khan, Hana M Dobrovolny

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.